The additional subcutaneous administration option expands Takeda's offering in this space, showing dedication to the HAE community while providing individualized treatment options to support ...

has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of YESINTEK, an Ustekinumab ...

SHANGHAI, China & JERSEY CITY, N.J., March 28, 2025--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA ...

The European Medicines Agency (EMA) on Friday recommended scrapping approval for a drug used to prolong gestation, citing a "possible but unconfirmed" risk of cancer. Healthcare ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

today announced that the European Medicines Agency (EMA) approved the Company’s Clinical Trial Application (CTA) for CLN-978. The Phase 1 clinical trial will assess CLN-978 in patients with ...

INDIANAPOLIS — A European ... Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency committee ...

TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE. 1 The Pre-Filled ...